The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.
about
Cannabinoids for Tourette's SyndromeCannabinoids in Tourette's syndromePositive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporterThe endocannabinoid system as an emerging target of pharmacotherapyN-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptorsLocalization and Function of GABA Transporters GAT-1 and GAT-3 in the Basal GangliaCognitive motor deficits in cannabis usersInhibition by anandamide of 6-hydroxydopamine-induced cell death in PC12 cells.Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's diseaseCannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.Endocannabinoid signaling in midbrain dopamine neurons: more than physiology?Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionFurther evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis.Differential localization and function of GABA transporters, GAT-1 and GAT-3, in the rat globus pallidus.CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation.Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?GABA transporter subtype 1 and GABA transporter subtype 3 modulate glutamatergic transmission via activation of presynaptic GABA(B) receptors in the rat globus pallidus.Interactions between CB(1) receptors and TRPV1 channels mediated by 12-HPETE are cytotoxic to mesencephalic dopaminergic neurons.Cannabinoid receptor signaling induces proliferation but not neurogenesis in the mouse olfactory epitheliumThe endocannabinoid system as a target for the treatment of motor dysfunction.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Management of tics and Tourette's disorder: an update.Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats.Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity.Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice.Cross-Cultural Effects of Cannabis Use Disorder: Evidence to Support a Cultural Neuroscience Approach.URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.Differential treatment regimen-related effects of HU210 on CB(1) and D(2)-like receptor functionality in the rat basal ganglia.
P2860
Q24240148-5C427DEB-E202-4170-A28C-851D0788570AQ24245682-132F0EE3-FD24-4C39-8F75-5D2E71F5763AQ24644993-0F3ADD95-FC53-4A33-8B95-45E87C09B6B5Q24648473-D8ECDC60-C57F-4938-9892-A857EC8FB1F6Q28244889-5CE397B9-01D1-4D34-B938-62673779D6E7Q28245673-6713A836-FFE6-4C78-AD1E-EFFAA2E82A9AQ28385443-D23B1533-DF75-4F1F-92C7-311BB9A5EC08Q33674608-089B7A29-7639-41E8-91B6-F65EF590C9DFQ33897801-0B3BD548-C5E7-471A-A0D6-9559B01A3946Q34269852-3BD4356B-E795-4CD3-BF06-3882AAC6895AQ34490167-28BD5774-25FA-46B6-8392-7E4F7EAC58D3Q34967151-4FF91D79-4EA0-4806-A55D-279F797392B5Q35499568-77991A2D-35EB-42F1-B786-AA7067937D94Q35571722-DB3D81BE-56FB-40E1-94C6-272D910C9D7EQ35602395-AD062287-C2E4-4B0F-B8A9-B56E8B89C7C1Q35820005-28491F2A-0DE2-4092-979B-A996F8A939FBQ36157657-2D2856F4-76BC-44C0-A3DA-1B7219E66F57Q36179607-DA08C560-EAE2-41FA-9E7B-0AF7FFCD5834Q36882571-F3273F22-A102-4CAA-B7B3-08FDD88F60BFQ37152051-7A5B074B-CFA9-4450-880B-DDAFF2341231Q37394164-40494F70-420E-4D43-BBF7-957E98B6A079Q37512670-C718A6A7-6CE1-4F8B-8EB1-ABBD007CD907Q37748795-93577ED2-BF67-44EA-BFC4-20218CDF58D6Q39359086-84B645CE-0231-47CD-810D-D40E3D18ADF0Q41809772-2F0884C7-20D5-41EA-92C0-5047A9E77A1EQ42156717-2CD62AEF-E51D-40A6-8C49-A9C3D9AC9ECEQ42655791-095244A4-ED74-44EE-8386-BBD724C47C77Q44343504-68D2134C-69AB-4B12-882B-10931EACF1EFQ48004283-DCE0B5F7-8B01-4150-924E-809CF5F75AAEQ48355383-BFA5F028-A401-4678-BAB8-8BCFB012704DQ48678685-68EE721C-B8C6-4607-B4CD-F340C0C536EE
P2860
The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@ast
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@en
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@nl
type
label
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@ast
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@en
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@nl
prefLabel
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@ast
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@en
The endogenous cannabinoid sys ...... ical, and therapeutic aspects.
@nl
P2093
P1476
The endogenous cannabinoid sys ...... gical, and therapeutic aspects
@en
P2093
Fernando Berrendero
Javier Fernández-Ruiz
José A Ramos
Rosario de Miguel
P304
P356
10.1016/S0163-7258(02)00253-X
P577
2002-08-01T00:00:00Z